Asoprisnil

From Wikipedia, the free encyclopedia

Jump to: navigation, search
Asoprisnil
Systematic (IUPAC) name
rel-4-[(8R,11S,13R,14R,17R)-17-Methoxy-17-

(methoxymethyl)-13-methyl-3-oxo- 2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro- 1H-cyclopenta[a]phenanthren-11-yl]benzaldehyde oxime
Identifiers
CAS number 199396-76-4
ATC code none
PubChem 9577221
Chemical data
Formula C28H35NO4 
Mol. mass 449.582 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?
Legal status
Routes  ?

Asoprisnil (J867) is an investigational selective progesterone receptor modulator developed by Schering and TAP Pharmaceutical Products, tested for treatment of progesterone sensitive myomata.[1]

In 2005, Phase III trials were discontinued due to endometrial changes in patients. It is uncertain whether asoprisnil will be marketed.[2]

[edit] References

  1. ^ DeManno D, Elger W, Garg R, et al. (2003). "Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy". Steroids 68 (10-13): 1019–32. doi:10.1016/j.steroids.2003.09.008. PMID 14667995. 
  2. ^ Schering Interim Report Q1-3 2005
v • d • e
Sex hormones and related agents (primarily G03, also L02, H01C) – human endogenous in SMALL CAPS
#WHO-EM. ‡Withdrawn from market. CLINICAL TRIALS: †Phase III. §Never to phase III


Stub icon This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
Stub icon This biochemistry article is a stub. You can help Wikipedia by expanding it.
Retrieved from "http://en.wikipedia.org/wiki/Asoprisnil"